Mezzion Pharma Co.Ltd (140410) — Cash Flow-to-Debt Ratio
Mezzion Pharma Co.Ltd (140410) has a Cash Flow-to-Debt Ratio of -0.08x as of December 2025, meaning its operating cash flow of ₩-6.84 Billion could theoretically repay 0% of its total liabilities (₩80.83 Billion) in one year. See Mezzion Pharma Co.Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mezzion Pharma Co.Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Mezzion Pharma Co.Ltd across 12 annual periods. Also explore Mezzion Pharma Co.Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Mezzion Pharma Co.Ltd (2012–2025)
Year-by-year debt coverage analysis for Mezzion Pharma Co.Ltd. For market capitalisation and broader financial context, see Mezzion Pharma Co.Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | ₩-16.59 Billion | ₩80.83 Billion | ▲ +69.0% |
| 2024 | -0.66x | ₩-18.49 Billion | ₩27.94 Billion | ▼ -84.4% |
| 2023 | -0.36x | ₩-11.02 Billion | ₩30.70 Billion | ▲ +17.4% |
| 2022 | -0.43x | ₩-12.07 Billion | ₩27.78 Billion | ▲ +39.0% |
| 2021 | -0.71x | ₩-15.07 Billion | ₩21.14 Billion | ▼ -81.8% |
| 2020 | -0.39x | ₩-7.38 Billion | ₩18.82 Billion | ▲ +69.9% |
| 2019 | -1.30x | ₩-20.88 Billion | ₩16.04 Billion | ▼ -6.3% |
| 2018 | -1.22x | ₩-21.72 Billion | ₩17.74 Billion | ▼ -93.4% |
| 2017 | -0.63x | ₩-13.21 Billion | ₩20.87 Billion | ▼ -349.0% |
| 2016 | -0.14x | ₩-6.08 Billion | ₩43.09 Billion | ▼ -422.4% |
| 2015 | 0.04x | ₩1.77 Billion | ₩40.52 Billion | ▼ -94.5% |
| 2012 | 0.79x | ₩3.14 Billion | ₩3.97 Billion | — |